| 货号 | MAB1849-SP |
| 简介 | Clone 210845 was used by HLDA to establish CD designation |
| 别名 | Activating natural killer receptor p30; CD337 antigen; CD337; CD337activating NK-A1 receptor; LY117,1C7NK-p30; lymphocyte antigen 117; natural cytotoxicity triggering receptor 3; Natural killer cell p30-related protein; NCR3; NKP30; NKp30MALS |
| 反应种属 | Human |
| 应用 | Flow Cytometry(2.5 µg/106cells) Agonist Activity(0.2-1.2 µg/mL) |
| 目标/特异性 | Detects human NKp30/NCR3 on cell transfectants and peripheral blood NK cells. |
| 使用方法 | Flow Cytometry: 2.5 µg/106cells Agonist Activity: 0.2-1.2 µg/mL |
| 来源 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 259197 (Human) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. | |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Mouse T cell hybridoma transfected with human NKp30/NCR3 and Mouse myeloma cell line NS0-derived recombinant human NKp30 Fc Chimera |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | NKp30, along with NKp44 and NKp46, constitute a group of receptors termed “Natural Cytotoxicity Receptors” (1). These receptors play a major role in triggering NK‑mediated killing of most tumor cells lines. NKp30 is a type I transmembrane protein having a single extracellular V-like immunoglobulin domain (2). A physical association with the ITAM-bearing accessory protein, CD3 zeta, occurs via a charged residue in the NKp30 transmembrane domain. Ligation of NKp30 with a specific antibody results in phosphorylation of CD3 zeta (3). NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset that account for more that 85% of NK cells found in peripheral blood and spleen (4). NKp30 is absent from the CD56bright, CD16- subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up-regulated in these cells upon IL-2 activation (4). Studies with neutralizing antibodies reveal that NKp30 is partially responsible for triggering lytic activity against several tumor cell types and that it is the main receptor responsible for NK‑mediated lysis of immature dendritic cells (2, 5). The ligand(s) recognized by NKp30 has not been described. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Human NKp30 Antibody Induces IFN‑ gamma Secretion in NK‑92 Cells. Human NKp30 Monoclonal Antibody induces IFN‑ gamma secretion in the NK-92 human natural killer lymphoma cell line in a dose-dependent manner, as measured using the Quantikine Human IFN‑ gamma ELISA Kit (Catalog # DIF50). The ED50 for this effect is typically 0.2‑1.2 μg/mL. |
